Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar User Fee Collections Rise, But Little Spent On Program Costs

Executive Summary

FDA attributes large carryover balance to uncertainty in knowing when it has reached statutory funding threshold that triggers access to fees.


Related Content

US FDA Biosimilar User Fee Collections, Expenditures Hit A High Point In 2017
The Big Spend-Down: US FDA Eyes $159M Reduction In Carryover User Fees
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
Biosimilars Program Will Be “Under-Resourced” In Early Years As Industry Grows





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts